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Efalizumab Therapy for Atopic Dermatitis Causes
Marked Increases in Circulating Effector Memory
CD4þ T Cells That Express Cutaneous Lymphocyte
Antigen
Erin G. Harper1, Eric L. Simpson1, Rodd H. Takiguchi1, Miranda D. Boyd2, Stephen E. Kurtz3,
Antony C. Bakke4 and Andrew Blauvelt1,3,4
Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from
blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and
peripheral blood mononuclear cells were analyzed for expression of activation and adhesion markers.
Efalizumab treatment led to decreases in CD11a mean fluorescence intensity (MFI) on naive, central memory,
and effector memory CD4þ and CD8þ T cell subsets. MFI for CD18 was decreased in both CD4þ and CD8þ
T cells. Percentages of cells positive for cutaneous lymphocyte antigen (CLA) were increased fourfold in all
CD4þ and CD8þ T cell subsets. Increases in the percentages of CD4þ and CD8þ T cells expressing b7 and
CD49d were also observed. No significant changes were observed in the percentages of CD4þ and CD8þ
T cells that produced either IFN-g or IL-4. In summary, efalizumab treatment resulted in (i) decreases in CD11a
and CD18 expression in all circulating T-cell subsets and (ii) increases in the percentages of blood T cells
expressing tissue homing markers (CLA, b7, CD49d). These data suggest that blockade of T-cell extravasation
into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation.
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INTRODUCTION
Lymphocyte function-associated antigen (LFA)-1 is a hetero-
dimer composed of the a-integrin CD11a and the b2-integrin
CD18 and is involved in T-cell extravasation from blood
into tissue (Butcher and Picker, 1996; Kupper and Fuhlbrigge,
2004). To exit blood vessels, T cells first go through a
selectin-mediated rolling phase, and these initially weak
interactions are reinforced through binding of LFA-1 on
T-cell surfaces with CD54 (intercellular adhesion molecule
(ICAM-1)) on endothelial cell surfaces (Butcher and Picker,
1996; Henderson et al., 2001; Kupper and Fuhlbrigge, 2004).
Following the rolling phase, T cells anchor via LFA-1 to
endothelial cell ICAMs and migrate into tissue. LFA-1 is
involved in the migration of T cells to sites of inflammation as
well as the migration of naı¨ve T cells into lymph nodes
(Berlin-Rufenach et al., 1999; Smith et al., 2007). Additio-
nally, T-cell adhesion to endothelium and naive T-cell
transmigration into lymph nodes is impaired in LFA-1 null
animals (Berlin-Rufenach et al., 1999; Henderson et al.,
2001), demonstrating the importance of LFA-1 in T-cell
extravasation. LFA-1 on T-cell surfaces also interacts with
CD54 on the surface of antigen-presenting cells to provide
co-stimulation and full T-cell activation (Hogg et al., 2002;
Joshi et al., 2006).
Efalizumab is a recombinant humanized mAb directed
against the CD11a subunit of LFA-1 (Joshi et al., 2006) and is
indicated for the treatment of individuals with moderate-
to-severe chronic plaque psoriasis. Approximately 30%
of patients will have at least 75% improvement of their
skin disease following a standard 12-week course of therapy
(drug is typically given subcutaneously at a weekly dose
of 1 mg kg1) (Gordon et al., 2003; Lebwohl et al., 2003;
Leonardi et al., 2005; Menter et al., 2005). Sustained efficacy
in the treatment of psoriasis patients over longer periods of
time has also been described (Lebwohl et al., 2003; Leonardi
et al., 2005; Menter et al., 2005). As patients improve, T-cell
numbers are reduced in healing skin, whereas T-cell numbers
are increased in peripheral blood (Krueger et al., 2000;
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Gottlieb et al., 2002; Vugmeyster et al., 2004), consistent
with efalizumab’s role in blocking T-cell extravasation
into skin. Although the drug has proven to be relatively safe,
with no reported increased incidence of infections in
treated patients (Langley et al., 2005), some individuals
who discontinue drug undergo a rebound of psoriasis (Carey
et al., 2006). Others have postulated a mechanism for disease
flare observed following drug discontinuation whereby skin-
homing peripheral blood T cells migrate into the skin after
efalizumab-induced restraints on extravasation are relieved.
Recently, we evaluated safety and clinical efficacy of
efalizumab in a 12-week pilot study in 10 individuals
with severe atopic dermatitis (Takiguchi et al., 2007), another
common inflammatory skin disease where the number
of cutaneous T cells are elevated (Homey et al., 2006;
Simpson and Hanifin, 2006; Wittmann and Werfel, 2006). In
these patients, reported herein, we examined cell-surface
antigen expression of adhesion molecules and homing
markers on various T-cell subsets in the blood. In addition,
cytokine secretion by activated blood T cells was quantified.
Our purpose was to gain further insight into the impact
of efalizumab treatment on the composition and activation
state of circulating T-cell populations. In addition to finding
marked increases in skin-homing T cells in the blood of
these patients, we found that treatment with efalizumab
caused general increases in circulating effector memory
T cells capable of homing to other tissues in the body. These
results suggest that efalizumab may be clinically useful for
both cutaneous and non-cutaneous T-cell-mediated diseases.
RESULTS
Efalizumab therapy increases the percentage of circulating
CD4þ effector memory T cells
As described below, T-cell populations were initially gated into
either CD3þCD4þ or CD3þCD8þ T cells. We defined
CD45RAþCD27þCD62Lþ cells as naive T cells, CD45RA
CD27þCD62Lþ cells as central memory T cells, and
CD45RACD27CD62L as effector memory T cells. The
mean ratio of CD4 to CD8 T cells present in the peripheral
blood of patients was 3.04, 2.09, 2.21, and 2.32 at days 0, 28,
56, and 84, respectively, reflecting a slight decrease in
the percentages of total circulating CD4þ T cells and a slight
increase in the percentages of total circulating CD8þ T cells,
although differences were not significant (Figure 1a).
Compared to baseline levels, examination of changes
in circulating T-cell subsets revealed significant increases in
the percentages of effector memory CD4þ T cells at days 56
(Po0.029) and 84 (Po0.007) following efalizumab therapy
(Figure 1b). In contrast, no differences in the percentages of
circulating effector memory CD8þ T cells were observed. In
addition, significant decreases in the percentages of CD4þ
central memory T cells were observed at days 56 (Po0.010)
and 84 (Po0.042). Minor decreases in CD8þ central
memory cells were observed, although these differences
were not statistically significant. Decreases in the percentages
of naive CD4þ (but not CD8þ ) T cells at days 28 (Po0.14),
56 (Po0.03), and 84 (Po0.13) were noted, although signi-
ficance was only achieved at day 56, likely due to high
interpatient variability. Minor, but not statistically significant,
decreases in CD8þ naive T cells were observed. These
data suggest that efalizumab therapy in humans with atopic
dermatitis preferentially redistributes effector memory CD4þ
T cells, altering the T-cell subset composition of the blood.
Efalizumab therapy decreases CD11a surface expression on
circulating T cells and expression levels correlate with clinical
improvement of atopic dermatitis
The percentages of CD4þ and CD8þ T cells expressing
CD11a, the target for efalizumab, were significantly reduced
at days 28, 56, and 84 (Figure 2a). Mean fluorescence inten-
sity (MFI) of CD11a on both CD4þ and CD8þ T cells was
also significantly reduced compared to baseline levels on
all days studied (Figure 2b).
When compared to baseline levels, CD11a expression was
significantly decreased on all six T-cell subsets on all days
studied (Figure 2c). For naive CD4þ T cells, CD11a levels
were decreased by 47.7% (Po0.003), 49.2% (Po0.002), and
47.4% (Po0.002) on days 28, 56, and 84, respectively, when
compared to baseline levels. For effector memory CD4þ
T cells, CD11a levels were decreased by 52.3% (Po0.001),
60.8% (Po0.001), and 59.9% (Po0.0001) on days 28, 56,
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Figure 1. Efalizumab therapy increases the percentage of circulating CD4þ
effector memory T cells. (a) The percentage of CD4þ and CD8þ T cells in
the blood was determined on the indicated days of the efalizumab treatment,
and the CD4þ /CD8þ ratio was slightly decreased during the course of
treatment, although differences did not reach statistical significance.
(b) The percentages of naive, effector memory, and central memory CD4þ
and CD8þ T cell subsets were determined on the indicated days of
efalizumab treatment and revealed an increase in the percentage of effector
memory CD4þ T cells in the blood; the percentages of CD4þ naive and
central memory T cells were decreased. No significant changes were observed
in the distribution of CD8þ T cell subsets, when compared to baseline levels.
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and 84, respectively. For central memory CD4þ T cells,
CD11a levels were decreased by 56.6% (Po0.0001), 59.4%
(Po0.001), and 59.8% (Po0.0001) on days 28, 56, and 84,
respectively. Similarly, for naive CD8þ T cells, CD11a levels
were decreased by 55.3% (Po0.0001), 56% (Po0.0001),
and 51.2% (Po0.0001) on days 28, 56, and 84, respectively.
For effector memory CD8þ T cells, CD11a levels were
decreased by 56.3% (Po0.0001), 64.9% (Po0.0001), and
66.9% (Po0.0001) on days 28, 56, and 84, respectively.
Finally, for central memory CD8þ T cells, CD11a expression
levels were decreased by 58.4% (Po0.0001), 59.5%
(Po0.0001), and 67.5% (Po0.0001) on days 28, 56, and
84, respectively.
Reduction of surface CD11a expression by T cells
correlated with clinical improvement in atopic dermatitis as
measured by the eczema area and severity index (EASI) score.
Analysis of expression levels of CD11a and EASI scores using
Pearson’s correlation yielded r values of 0.37 (Po0.018) for
naive CD4þ cells, 0.41 (Po0.008) for effector memory
CD4þ T cells, 0.45 (Po0.004) for central memory CD4þ
T cells, 0.51 (Po0.0007) for naive CD8þ T cells, 0.48
(Po0.0015) for effector memory CD8þ T cells, and 0.434
(Po0.005) for central memory CD8þ T cells. These data
indicate that a moderate relationship exists between CD11a
surface expression levels and clinical improvement of
atopic dermatitis secondary to efalizumab therapy.
Efalizumab therapy decreases CD18 surface expression on
circulating T cells
The b-subunit of the LFA-1 heterodimer is CD18 (Butcher and
Picker, 1996; Kupper and Fuhlbrigge, 2004). Consistent with
a reduction in the number of T cells expressing CD11a, the
percentage of total T cells expressing CD18 was decreased
by 27.55, 17.16, and 17.23%, although differences were not
statistically significant.
The percentage of CD4þ T cells expressing CD18 was
significantly reduced by 36.0% (Po0.043), 28.3% (Po0.011),
and 24.8% (Po0.020) at days 28, 56, and 84, respectively
(Figure 3a). Patients receiving efalizumab exhibited a decrease
of 21.0%, 11.5%, and 11.1% in the percentage of CD8plus;T
cells expressing CD18 at days 28, 56, and 84, respectively,
when compared to baseline expression, although differences
were not statistically significant. When compared to baseline
levels, analysis of CD18 surface protein levels indicated
a decrease of 27.6% (Po0.026), 34.65% (Po0.007), and
33.2% (Po0.003) at days 28, 56, and 84, respectively.
CD18 expression on CD4þ T cells was decreased by 30.1%
(Po0.013), 33.1% (Po0.008), and 31.33% (Po0.002), where-
as CD8þ T cells decreased CD18 expression by 41.1%
(Po0.016), 58.9% (Po0.005), and 57.7% (Po0.006) on all
treatment days studied (Figure 3b).
Levels of CD18 protein were reduced on all CD4þ and
CD8þ T-cell subsets examined. Naive CD4þ T cells
exhibited 30.7% (Po0.024), 29.7% (Po0.063), and 26.9%
(Po0.026) decreases on days 28, 56, and 84, respectively,
compared to baseline levels (Figure 3c). On effector memory
CD4þ T cells, CD18 levels decreased by 53.4% (Po0.036),
27.5% (Po0.038), and 40.1% (Po0.057) on days 28, 56, and
84, respectively. On central memory CD4þ T cells, CD18
levels decreased by 42.8% (Po0.0002), 43.7% (Po0.0018),
and 43.8% (Po0.0006) on days 28, 56, and 84, respectively.
CD18 expression by naive CD8þ T cells decreased by
37.2% (Po0.0005), 24% (Po0.051), and 20.6% (Po0.124)
on days 28, 56, and 84, respectively, compared to baseline.
Effector memory CD8þ T cell expression of CD18 was
decreased by 48.1% (Po0.0006), 52.2% (Po0.0008), and
53.9% (Po0.0003) on days 28, 56, and 84, respectively.
Finally, central memory CD8þ cells decreased expression
by 46.2% (Po0.0006), 57.5% (Po0.0005), and 56.0%
(Po0.0012) on days 28, 56, and 84, respectively.
Decreased levels of CD18 correlated with clinical improve-
ment but to a lesser degree than the decreases observed with
cell-surface levels of CD11a. CD18 downregulation on central
memory CD4þ T cells, naive CD8þ T cells, effector memory
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Figure 2. Efalizumab therapy decreases CD11a surface expression on
circulating T cells. (a) The percentages of CD11aþ T cells, CD4þ T cells,
and CD8þ T cells in the blood during the course of efalizumab treatment
were determined on the indicated days and revealed significantly decreased
percentages of all T-cell subgroups expressing CD11a, when compared to
patient baseline levels. (b and c) Significantly decreased levels of CD11a
surface protein expression on circulating T cells, CD4þ T cells, and CD8þ
T cells was also observed on the indicated days in response to efalizumab
therapy as well as decreased CD11a expression levels on all naive, effector
memory, and central memory CD4þ and CD8þ T-cell subset populations.
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CD8þ T cells, and central memory CD8þ T cells correlated
with decreased EASI scores, yielding Pearson correlation
coefficient values of 0.41 (Po0.0094), 0.35 (Po0.029), 0.47
(Po0.002), and 0.40 (Po0.01), respectively. Decreased CD18
expression by naive and effector memory CD4þ T cells did
not significantly correlate with decreased EASI scores.
Efalizumab therapy increases the percentage of circulating
T cells that express CLA, a skin-homing marker
Previous studies have shown that cutaneous lymphocyte
antigen (CLA) binds E-selectin, which is expressed on dermal
endothelial cells, and that this interaction mediates T-cell
extravasation into skin (Butcher and Picker, 1996; Kupper
and Fuhlbrigge, 2004). Patients receiving efalizumab exhib-
ited significant increases in the percentages of circulating
total T cells, CD4þ T cells, and CD8þ T cells expressing
CLA (Figure 4a). Baseline mean values ranged approximately
8–14% in these three T-cell populations, and the mean values
increased to 31–48% on the various treatment days, indi-
cating consistent fourfold increases in the percentages of
CLA-expressing T cells (Figure 4a). By contrast, there was a
trend toward decreased CLA surface-expression levels on
most T-cell populations (Figure 4b). Examination of T-cell
subsets indicated that the percentage of naive CD4þ T cells
in the blood expressing CLA increased over baseline levels by
30.0% (Po0.02), 29.2% (Po0.008), and 32.3% (Po0.0001)
on 28, 56, and 84 days of treatment, respectively (Figure 4c).
The number of effector memory CD4þ T cells expressing
CLA increased by 28.6% (Po0.011), 19.7% (Po0.022), and
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Figure 3. Efalizumab therapy decreases CD18 surface expression on
circulating T cells. (a) The percentages of CD18þ T cells, CD4þ T cells, and
CD8þ T cells in the blood during the course of efalizumab treatment were
determined on the indicated days, and the percentages of total T cells and
CD4þ T cells, but not CD8þ T cells, expressing CD18 were significantly
decreased. (b and c) CD18 surface protein expression on total circulating
T cells, CD4þ T cells, and CD8þ T cells was decreased on the indicated
days of efalizumab treatment as well as on all naive, effector memory,
and central memory CD4þ and CD8þ T-cell subsets.
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Figure 4. Efalizumab therapy increases the percentage of circulating T cells
that express CLA, a skin-homing marker. (a) The percentages of T cells,
CD4þ T cells, and CD8þ T cells in the blood expressing CLA during the
course of efalizumab treatment were determined on the indicated days and
were shown to be significantly elevated when compared to patient baseline
levels. (b) By contrast, surface protein expression levels of CLA on total
circulating T cells, CD4þ T cells, and CD8þ T cells were decreased on
the indicated days of efalizumab treatment. (c) When compared to baseline
levels, the percentages of CLA-expressing T cells markedly increased in
all T-cell subset populations, except for central memory CD8þ T cells,
where increases failed to meet significance.
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28.0% (Po0.0001), whereas the percentage of central
memory CD4þ T cells expressing CLA increased by 23.6%
(Po0.024), 20.2% (Po0.007), and 28.5% (Po0.0001)
on days 28, 56, and 84, respectively, when compared
to baseline levels. The number of naive CD8þ T cells
expressing CLA increased by 31.1% (Po0.008), 30.4%
(Po0.001), and 33.8% (Po0.0001) on days 28, 56, and
84, respectively. Percentages of effector memory CD8þ
T cells expressing CLA increased by 33.1% (Po0.001),
27.1 (Po0.001), and 25.4% (Po0.003) on days 28, 56,
and 84, respectively, when compared to baseline levels.
Finally, percentages of CLAþ central memory CD8þ T cells
increased by 17.3, 11.9, and 14.8% on days 28, 56, and 84 of
efalizumab treatment compared to baseline levels, though
these differences were not statistically significant. Despite
consistent increases in the numbers of CLA-expressing T cells
in blood, no significant correlations were detected between
increasing blood CLAþ T cells and the clinical EASI score
among individual patients.
Efalizumab therapy increases the percentage of circulating
T cells that express b7/CD49d, a gut-homing marker
The b7 interacts with CD49d, and together this heterodimeric
molecule is involved in T-cell movement from peripheral
blood into gastrointestinal tissue (Butcher and Picker, 1996;
Kupper and Fuhlbrigge, 2004). Percentages of total T cells,
CD4þ T cells, and CD8þ T cells expressing b7 in the
blood increased slightly, although these increases were not
statistically significant (Figure 5a). By contrast, and yet similar
to CLA, b7 surface expression levels were significantly
downregulated on both total T cells and CD4þ T cells. b7
surface expression levels of total T cells were decreased by
49.3% (Po0.020), 35.7% (Po0.007), and 31.7% (Po0.004).
Expression levels on CD4þ T cells were decreased by
52.2% (Po0.050), 40.8% (Po0.015), and 32.2% (Po0.005)
at days 28, 56, and 84, when compared to baseline levels,
although differences were not detected in CD8þ T cells
(Figure 5b).
Percentages of circulating CD49dþCD4þ T cells mark-
edly increased by 106.5% (Po0.008) and 114.9% (Po0.001)
on days 56 and 84, respectively (Figure 5c). Percentages
of total T cells and CD8þ T cells expressing CD49d
also increased, although a statistically significant difference
was only observed for total CD49dþ T cells on day 84
(Po0.029). Consistent with the observed decreases in
CLA and b7 surface expression levels, decreases in CD49d
MFI by 46.7% (Po0.011), 61.0% (Po0.00018), and 55.2%
(Po0.0006) were observed on total T cells on days 28, 56,
and 84, respectively, when compared to baseline levels
(Figure 5d). CD4þ T-cell expression levels of CD49d
were significantly reduced by 47.3% (Po0.013), 62.6%
(Po0.0001), and 59.6% (Po0.0005) on days 28, 56, and
84, respectively. Finally, CD8þ T cells exhibited a 24.0%
(Po0.236), 55.4% (Po0.0034), and 39.6% (Po0.065)
reduction in CD49d expression on days 28, 56, and 84,
when compared to baseline levels.
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Figure 5. Efalizumab therapy increases the percentage of circulating T cells that express b7/CD49d, a gut-homing marker. (a) The percentages of T cells,
CD4þ T cells, and CD8þ T cells in the blood expressing b7 during the course of efalizumab treatment were determined on the indicated days and were found
to be significantly elevated when compared to patient baseline levels. (b) Surface protein expression levels of b7 on total circulating T cells, CD4þ T cells, and
CD8þ T cells were determined on the indicated days of efalizumab treatment and were found to be decreased when compared to baseline levels, although
decreased b7 integrin surface protein expression on CD8þ T cells was not statistically significant. (c) The percentages of T cells, CD4þ T cells, and CD8þ
T cells in the blood expressing CD49d during the course of efalizumab treatment were determined on the indicated days and were found to be significantly
elevated when compared to patient baseline levels. (d) Surface protein expression levels of CD49d on total circulating T cells, CD4þ T cells, and CD8þ
T cells were determined on the indicated days of efalizumab treatment and were found to be decreased when compared to baseline levels, although
decreased CD49d surface protein expression on CD8þ T cells was only significant on day 84.
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Efalizumab therapy increases CD44 surface expression on
circulating T cells
CD44 is an adhesion receptor that is upregulated, when
compared to naive T cells, on the surface of memory T cells.
In this study, essentially all circulating T cells expressed
CD44, and there was no effect on this percentage as a result
of treatment (data not shown). By contrast, CD44 surface
expression level on total T cells markedly increased by 90.7%
(Po0.0003), 81.4% (Po0.0001), and 104.9% (Po0.00002)
on days 28, 56, and 84, respectively, of efalizumab therapy
(Figure 6). Similarly, CD44 levels on CD4þ T increased
by 102.7% (Po0.0002), 89.3% (Po0.00002), and 113.6%
(Po0.00007) on days 28, 56, and 84, respectively, post-
initiation of treatment. Finally, CD44 MFI on CD8þ T cells
increased by 75.5% (Po0.0003), 80.67% (Po0.0001), and
95.7% (Po0.00004) on days 28, 56, and 84, respectively,
when compared to baseline.
Minor, but not significant, decreases in the percentages of
stimulated T cells that produce IFN-c during efalizumab therapy
Efalizumab can inhibit full T-cell activation in vitro by
blocking the co-stimulatory pairing of CD54 on antigen-
presenting cells and CD11a on T cells (Joshi et al., 2006). To
determine whether efalizumab therapy in humans functioned
in this manner, we examined the ability of stimulated 1-day-
cultured peripheral blood mononuclear cells (PBMCs), iso-
lated from our efalizumab-treated patients, to produce either
IFN-g or IL-4. Over the course of therapy, we noted slight,
but not statistically significant, decreases in the percentages
of both CD4þ and CD8þ T cells that produced IFN-g
(Figure 7). There was a slight decrease in the percentage
of CD4þ T cells that produced IL-4 and a slight increase in
the percentage of CD8þ T cells that produced IL-4, although
these observed changes in cytokine production were also not
statistically significant.
DISCUSSION
In this report, we found that treatment of severe atopic derma-
titis patients with efalizumab, a humanized mAb directed
against CD11a, led to striking immunologic changes in
circulating T-cell populations. Details on the clinical efficacy
seen in our patients have been reported (Takiguchi et al.,
2007). Examination of the peripheral T-cell compartment by
eight-color flow cytometry during the course of therapy
revealed decreases in CD11a, the drug’s target molecule, and
CD18, the heterodimeric partner of CD11a, on all T-cell
subsets (Figures 2 and 3). These data are consistent with
internalization of cell-surface CD11a/CD18 heterodimers
and are consistent with previous reports that examined
efalizumab’s mechanism of action in patients with psoriasis
(Gottlieb et al., 2002; Vugmeyster et al., 2004; Mortensen
et al., 2005). It is also possible that those cells expressing high
levels of CD11a bind increased amounts of efalizumab in the
blood and are cleared more efficiently from the blood stream,
resulting in the selection of a T-cell population that expresses
lower levels of CD11a. Downregulation of both CD11a and
CD18 correlated with individual clinical responses to
therapy.
We also documented dramatic increases in percentages
of circulating memory T cells, especially effector memory
CD4þ T cells, that expressed tissue homing markers (CLA,
b7, and CD49d) during efalizumab treatment (Figures 4 and
5). The cellular infiltrate in the skin of atopic dermatitis
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Figure 6. Efalizumab therapy increases CD44 surface expression on
circulating T cells. CD44 surface protein expression levels on total circulating
T cells, CD4þ T cells, and CD8þ T cells were determined on the indicated
days of efalizumab treatment. Expression levels of CD44 were significantly
increased on all T-cell populations and on all days when compared to
baseline levels.
20
18
16
14
12
10
8
6
4
2
0
Pe
rc
e
n
ta
ge
 o
f 
su
bp
op
ul
at
io
n
ex
pr
es
sin
g 
IF
N-
γ
Pe
rc
e
n
ta
ge
 o
f 
su
bp
op
ul
at
io
n 
ex
pr
es
sin
g 
IL
-4
CD4+
CD8+
CD4+
CD8+
Treatment duration (days)
0 28 *
* *
56 84
Treatment duration (days)
0 28 56 84
8
7
6
5
4
3
2
1
0
Figure 7. Minor, but not significant, decreases in the percentages of
stimulated 1-day-cultured blood-derived T cells that produce IFN-c during
efalizumab therapy. (a) The percentages of cells expressing IFN-g were
determined through intracellular staining of 1-daycultured T cells on the
indicated days and found to be slightly decreased during efalizumab therapy,
although differences were not statistically significant. (b) The percentages
of cells expressing IL-4 were determined through intracellular staining of
1-day-cultured T cells on the indicated days and found to be slightly
increased during efalizumab therapy, although differences were not
statistically significant.
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patients consists primarily of CD4þ memory T cells, and
thus it is not unexpected that the number of these T cells
would increase in blood in concert with healing of skin
lesions in this disease (Wakita et al., 1994; Watanabe et al.,
1994). Of these data, perhaps our most striking finding was
that percentages of circulating T cells that expressed CLA, a
predominant skin-homing marker, increased fourfold during
treatment with efalizumab (Figure 4). It has been reported that
increased numbers of CLAþ T cells are present in atopic
dermatitis lesions when compared to non-lesional skin or skin
from healthy individuals (de Vries et al., 1997). In addition,
there are increased numbers of CLAþ T cells in the blood
of patients with untreated atopic dermatitis, and a higher
percentage of these CLAþ T cells express b7, CD49d,
and CD11a compared to healthy controls (Seneviratne et al.,
2007). Although we did not examine lesional skin in our
study, a recent report showed that T cells are markedly
reduced in previously affected skin following successful
treatment of atopic dermatitis with efalizumab (Hassan et al.,
2007). Taken together, we believe there are two likely
mechanisms involved in the marked accumulation of CLAþ
T cells in the blood of our patients: (i) T cells could not enter
into the skin due to impairment of CD11a function and
(ii) CLAþ T cells present in inflamed atopic dermatitis skin
before therapy returned to the circulation as skin disease
improved during therapy. Further study will be required to
define the mechanism regulating CLAþ T cell accumulation
in the blood.
CLAþ T cells accumulating during efalizumab therapy
may be capable of entering into cutaneous tissue upon
cessation of treatment and relief of the inhibition of T-cell
trafficking. Indeed, our data regarding increased CLAþ
T cells in the blood of efalizumab-treated patients likely
explain skin disease flares observed in 10–15% of psoriasis
patients upon discontinuation of this drug (Leonardi, 2004).
This rebound phenomenon was observed in one patient in
this study (Takiguchi et al., 2007). Combination drug
treatment at the time efalizumab is discontinued (e.g., by
adding cyclosporine or methotrexate for a brief period of
time) may prevent disease flare and is now often practiced by
clinicians. In addition, combination therapy with efalizumab
and a drug that induces T-cell apoptosis, such as alefacept
(Vaishnaw and TenHoor, 2002; Krueger and Callis, 2003), a
tumor necrosis factor-a blocker, or even photopheresis may
effectively synergize to kill circulating CLAþ T cells that are
elevated by efalizumab therapy. If this were the case, efficacy
in treating skin disease would be expected to be much greater
when two types of treatment with differing mechanisms
of action are combined when compared to efficacy achieved
with either drug type alone. Of interest, several cases
describe successful combination use of efalizumab and
tumor necrosis factor-a blockers for patients with severe
psoriasis (Lowes et al., 2005).
Increased numbers of b7-positive T cells are also present
in atopic dermatitis lesions when compared to non-lesional
skin or skin from healthy individuals (de Vries et al., 1997). A
significant gut-homing integrin receptor is formed by hetero-
dimerization of b7 with CD49d (Hamann et al., 1994). We
observed increased percentages of both b7- and CD49d-
expressing T cells in the blood of our patients, whereas the
surface protein expression levels of both proteins were
decreased. The accumulation of both b7- and CD49d-
positive circulating T cells suggests that efalizumab may also
act to disrupt T-cell trafficking to mucosal tissue. Of interest,
our findings that efalizumab increases percentages of b7 and
CD49dþ gut-homing T cells (Figure 5) and decreases T-cell
activation (Figure 7) suggests that this drug may indeed
be effective for inflammatory bowel disease. Further study is
necessary to determine whether other T-cell-mediated
inflammatory conditions may also respond to efalizumab
via similar immunologic mechanisms.
b7 can also bind with CD103, forming a receptor that
interacts with E-cadherin, which is expressed on keratino-
cytes. The b7/CD103 heterodimer functions to retain T cells
within epidermis (Karecla et al., 1996). It has been reported
that b7/CD103þ T cells accumulate in psoriasis lesions and
that b7/CD103 appears to be involved in T-cell recruitment
and retention in inflamed skin (Pauls et al., 2001; Rottman
et al., 2001). A reduction in T-cell b7/CD103 surface protein
expression levels in atopic dermatitis patients may facilitate
T-cell migration from the tissue, thereby promoting emigra-
tion of resident T cells from the skin and further contributing
to the accumulation of b7þ T cells in the blood.
A significant increase in surface expression of CD44, the
receptor for hyaluronan, was also observed on circulating
T cells during efalizumab therapy. CD44 expressed by endo-
thelial cells binds hyaluronan, which in turn is bound by
CD44 expressed by skin-infiltrating T cells (Mohamadzadeh
et al., 1998). CD44–hyaluronan interactions allow T cells to
anchor to the vascular endothelium, facilitating extravasation
(Mohamadzadeh et al., 1998). CD44 surface protein expres-
sion is increased on T cells during disease progression in
an IL-4 transgenic mouse model for atopic dermatitis (Chen
et al., 2005), and CD44 is required for cutaneous T-cell
infiltration in a mouse model for atopic dermatitis (Gonda
et al., 2005). Thus, we postulate that increased CD44 surface
expression of levels on circulating T cells in our patients
reflects blockade of effector memory T-cell infiltration into
skin, with subsequent accumulation of these cells within
the blood.
Efalizumab is theoretically capable of decreasing cuta-
neous inflammation through several mechanisms: decreased
T-cell trafficking from blood into skin through interruption
of LFA-1/ICAM-1 interactions, decreased T-cell activation
by blocking co-stimulatory signaling between T cells and
antigen-presenting cells, decreased naive T-cell trafficking
into lymph nodes, and increased clearance of antibody-
coated T cells. Our data suggest that inhibition of blood-to-
tissue trafficking is the dominant mode of action for this drug
in the treatment of patients with atopic dermatitis. Although
T cells produced less IFN-g during efalizumab therapy,
indicating T-cell activation levels were dampened, these
changes were not statistically significant. Impaired trafficking
of naive T cells into lymph nodes likely did not occur in our
patients, as populations of memory, not naive, T cells were
elevated with treatment. In summary, our findings likely
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reflect the fact that efalizumab produces dramatic blockade
of memory CD4þ T-cell extravasation from blood into skin
as well as other tissues, suggesting that efalizumab may be
clinically useful for a variety of both cutaneous and non-
cutaneous T-cell-mediated diseases.
MATERIALS AND METHODS
Patients and sample collection
The Oregon Health & Science University Institutional Review Board
approved all aspects of this study according to the Declaration of
Helsinki Principles. After giving informed consent, 10 patients were
enrolled in a 12-week open-label study to determine the efficacy and
safety of efalizumab in treating moderate-to-severe atopic dermatitis
(Takiguchi et al., 2007). All subjects received an initial conditioning
dose of 0.7 mg kg1 of efalizumab at day 0 and doses of 1 mg kg1
weekly, beginning on day 7 and ending on day 77. Patients were
assigned an EASI score. The EASI scores for each patient were
determined weekly, and changes in EASI score determined clinical
improvement in response to efalizumab treatment. A quantity of 15
ml of blood was collected on days 0, 28, 56, and 84 before the
weekly administration of efalizumab, and PBMCs were isolated from
blood using Ficoll-hypaque (Amersham, Piscataway, NJ) gradient
separation.
Reagents
The following mouse anti-human mAbs and corresponding isotype
control Abs were purchased from BD Biosciences (San Jose, CA)
unless otherwise noted: unconjugated CD3 (clone: UCHTI),
phycoerythrin (PE)-Cy7-conjugated CD4, PE-Cy5.5-conjugated
CD8, Pacific Blue-conjugated CD45RA (Caltag, Burlingame, CA),
APC-conjugated CD62L, APC-Cy7-conjugated CD27 (Ebioscience,
San Diego, CA), FITC-conjugated CD11a (clone HI111 recognizes
an epitope distinct from that recognized by efalizumab),
CD18, CD44 (Beckman Coulter, Fullerton, CA), CLA, IFN-g, and
PE-conjugated CD11b, CD11c, CD49d, b7, and IL-4.
Immunostaining and flow cytometry on freshly isolated PBMCs
Freshly isolated PBMCs were suspended in staining buffer (10% fetal
bovine serum solution in PBS) and aliquots of 1 106 cells were
placed in five separate tubes. All mAbs described below were used
at a final concentration of 10 mg ml1. Four samples were incubated
with an anti-CD3 mAb for 30 minutes, washed twice with staining
buffer, and incubated with an Alexa-Fluor 430 conjugated goat anti-
mouse secondary Ab (Invitrogen, Carlsbad, CA) for 30 minutes at
41C. Cells were then washed twice with staining buffer and
incubated with 10 mg of whole mouse IgG to block any unbound
anti-mouse secondary Ab. Directly conjugated Abs (CD4 PE-Cy7,
CD8 PE-Cy5.5, CD45RA Pacific Blue, CD62L APC, CD27 APC-Cy7)
were then added to each of the four samples. Next, CD11a FITC and
CD11b PE were added to one sample, CD18 FITC and CD11c PE
were added to the second sample, CD44 FITC and CD49d PE were
added to the third sample, and CLA FITC and b7 PE were added to
the fourth sample. The final tube of cells was incubated with a
mixture of fluorophore-conjugated isotype control Abs. Cells were
incubated with these combinations of directly conjugated mAbs for
30 minutes, washed twice with staining buffer, and resuspended in
staining buffer for flow cytometric analysis using an LSRII and
FacsDiva software (BD Biosciences, San Jose, CA). One hundred
thousand total events were collected and analyzed from each
sample.
Immunostaining and flow cytometry on cultured PBMCs
An aliquot of freshly isolated PBMCs from each patient on each day
was washed twice in sterile PBS. PBMCs were then plated into 12-well
culture dishes coated with or without anti-CD3 mAbs containing
Roswell’s Park Memorial Institute with 10% fetal bovine serum,
100mg ml1 streptomycin, and 100 U ml1 penicillin (Gibco, Grand
Island, NY). Recombinant human interleukin-2 (R&D Systems,
Minneapolis, MN) and anti-CD28/CD49d mAbs (BD Biosciences, San
Jose, CA) were added to cells incubated with anti-CD3 mAbs to provide
co-stimulatory signals. After 20 hours of culture, both unstimulated and
stimulated PBMC cultures were treated with a 1,000-fold dilution of
Golgi Plug containing brefeldin A (BD Biosciences) and incubated for
an additional 4 hours to allow for intracellular cytokine accumulation.
PBMCs were then centrifuged, washed twice, and resuspended in
staining buffer. Cells were stained for surface antigen expression, as
described above, using mouse anti-human CD3, CD4, CD8 CD62L,
CD45RA, and CD27 mAbs. PBMCs were then washed twice, fixed and
permeabilized using the Cytofix/Cytoperm kit (BD Bioscience), and
stained with mouse anti-human IFN-g and mouse anti-human IL-4.
Samples were analyzed by flow cytometry as described above.
Definitions of T-cell subsets and statistical analyses
T-cell populations analyzed by flow cytometry were initially gated into
either CD3þCD4þ or CD3þCD8þ T cells. We defined CD45RAþ
CD27þCD62Lþ cells as naive T cells, CD45RACD27þCD62Lþ
cells as central memory T cells, and CD45RACD27CD62L cells
as effector memory T cells on the basis of previous classifications
(Butcher and Picker, 1996; Kupper and Fuhlbrigge, 2004). For each
antigen (CD11a, CD18, CD44, CD49d, CLA, and b7) and for each of
the six T-cell subsets (naive CD4þ , naive CD8þ , central memory
CD4þ , central memory CD8þ , effector memory CD4þ , and effector
memory CD8þ ) and at each time point (days 0, 28, 56, and 84), the
percentage of positive cells and the MFI were determined. Significant
changes in antigen expression levels in response to efalizumab
treatment were detected using a two-tailed Student’s paired t-test. The
percentage of T cells expressing each antigen and the antigen MFI
values at baseline were compared to expression and percentage values
obtained at days 28, 56, and 84. Pearson’s correlation coefficients were
calculated to determine whether a relationship existed between antigen
expression levels during the course of efalizumab treatment and patient
clinical scores.
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